NOV 10-12, 2027 BALTIMORE, MD IN-PERSON

Where cell & gene therapy moves from bench to bedside

NexCGT-2027 gathers the scientists, clinicians, and manufacturers turning gene editing, engineered cells, and RNA therapeutics into approved treatments - three days of data, debate, and deal-making in Baltimore.

About the conference

The edition of a field-defining gathering

NexCGT-2027 takes place November 10-12, 2027 in Baltimore, organized by Impact Research Communications. As its first edition, the conference sets out to become a leading international meeting point for the people building the next generation of advanced therapeutics.

Researchers, clinicians, biotech founders, pharmaceutical leaders, and regulators will spend three days working through the science, the trial data, and the commercialization questions that decide whether a therapy reaches patients.

3days of keynotes, panels, and scientific sessions
6tracks spanning discovery through commercial launch
Why attend

Four reasons this is where you need to be

PARTNERSHIPS

Collaboration & strategic partnerships

Academia, biotech, pharma, and investors sit in the same room - built for the collaborations that actually move a program forward.

SCIENCE

Transformative research & innovation

Gene editing, CRISPR, engineered cell therapies, regenerative medicine, and RNA therapeutics, presented by the labs doing the work.

NETWORK

Networking & industry access

Structured sessions and open floor time to meet researchers, clinicians, regulators, and the investors funding what's next.

MARKET

Commercialization & what's ahead

Manufacturing, regulatory pathways, and AI-driven approaches to getting an approved therapy to the patients who need it.

Scientific sessions

Six tracks, from discovery to launch

Every track runs across all three days. Expand a track to see its focus areas.

Current State and Future Directions in Cell & Gene Therapy
Translational Research Strategies for Accelerating Clinical Development
Advances in Gene Editing Technologies and Therapeutic Applications
Stem Cell and Regenerative Medicine: Clinical Translation and Emerging Therapies
Cell Reprogramming and Next-Generation Regenerative Approaches
RNA-Based Therapeutics and Gene Modulation Technologies
Non-Viral and Novel Gene Delivery Platforms
Personalized and Precision Cell & Gene Therapies
Translational Challenges in Rare and Genetic Diseases
Clinical Development of Cell & Gene Therapies for Oncology
Neurodegenerative and Neuromuscular Disease Therapeutics
Emerging Therapeutic Applications Beyond Rare Diseases
Real-World Evidence and Long-Term Patient Outcomes
Clinical Trial Design and Patient-Centric Development Strategies
CRISPR, Base Editing, Prime Editing and Beyond
Precision Genome Engineering for Next-Generation Therapies
In Vivo vs Ex Vivo Gene Editing Strategies
Engineering Immune Cells: CAR-T, CAR-NK, TCR-T and Beyond
Multiplex Gene Editing and Synthetic Biology Approaches
Gene Editing for Hematological and Inherited Disorders
Engineering Stem Cells for Regenerative Applications
Novel Vector Technologies and Targeted Delivery Systems
AI-Driven Target Identification and Therapeutic Design
Gene Editing Safety, Off-Target Analysis and Risk Mitigation
Translational Models for Gene Editing and Cell Therapy Development
Emerging Genome Engineering Platforms and Future Technologies
Clinical Trial Design for Cell & Gene Therapies
Patient Recruitment, Diversity and Retention Strategies
Biomarkers, Companion Diagnostics and Patient Selection
Clinical Safety Monitoring and Long-Term Follow-Up
Real-World Evidence and Post-Marketing Data Generation
Translational Medicine Approaches for Accelerating Development
Clinical Success Stories and Lessons Learned
Global Clinical Development Strategies
Digital Health and AI in Clinical Trial Management
Patient Access and Treatment Adoption
Scaling Cell & Gene Therapy Manufacturing for Commercial Success
Process Development and Tech Transfer Strategies
Viral Vector Manufacturing and Capacity Expansion
Next-Generation Non-Viral Manufacturing Platforms
Automation, Robotics and Digital Manufacturing
AI and Data Analytics in Bioprocess Optimization
GMP Compliance and Quality-by-Design Approaches
Quality Control, Release Testing and Comparability
Closed-System Manufacturing Technologies
Decentralized and Point-of-Care Manufacturing Models
Cold Chain Logistics and Global Distribution Strategies
Supply Chain Resilience and Risk Management
CDMO Partnerships and Outsourcing Models
Cost Reduction and Manufacturing Economics
Sustainable Manufacturing for Advanced Therapies
Global Regulatory Landscape for Cell & Gene Therapies
FDA, EMA and International Regulatory Perspectives
Accelerated Approval Pathways and Expedited Programs
Regulatory Considerations for Gene Editing Technologies
CMC Strategies for Regulatory Success
Pharmacovigilance and Long-Term Safety Monitoring
Market Access and Reimbursement Strategies
Value Demonstration and Health Economics
Innovative Pricing Models for Advanced Therapies
Commercial Launch Readiness and Market Entry Planning
Intellectual Property, Licensing and Technology Transfer
Strategic Partnerships, M&A and Investment Trends
Venture Capital and Funding Opportunities in Cell & Gene Therapy
Commercial Success Stories and Lessons from Approved Products
Academia-Industry Collaboration Models
Building Successful Translational Research Ecosystems
Biotech Startups and Emerging Innovation Platforms
Investment Trends in Cell & Gene Therapy
Strategic Alliances and Partnering Opportunities
Technology Commercialization and Licensing Strategies
Public-Private Partnerships in Advanced Therapeutics
Future Outlook: The Next Decade of Cell & Gene Therapy

Secure your place in Baltimore

Start your conference journey early with pre-early-bird registration

Register now